VCYT - Veracyte, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$57.83
DETAILS
HIGH:
$66.00
LOW:
$47.00
MEDIAN:
$58.50
CONSENSUS:
$57.83
UPSIDE:
1.81%
About Veracyte, Inc. (https://www.veracyte.com)
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Marc A. Stapley | Chief Executive Officer & Director | 1970 | $1,531,000 USD |
| Phillip G. Febbo | Chief Scientific & Medical Officer | 1966 | $930,089 USD |
| Rebecca Chambers | Executive Vice President & Chief Financial Officer | 1978 | $911,950 USD |
| John Leite | Global Chief Commercial Officer | 1972 | $846,485 USD |
| Annie McGuire | Executive VP, General Counsel & Head of Market Access | 1981 | $829,500 USD |
| Jonathan Wygant | Vice President & Chief Accounting Officer | 1971 | – |
| Keith Gligorich | Senior Vice President of Global Operations | – | – |
| Kelly Gura | Director of Investor Relations | – | – |
| Kevin Richard Haas | Chief Development and Technology Officer | 1985 | – |
| Steven French | Senior Vice President & Chief Information Officer | – | – |